按产品类型、治疗用途和地区分類的生物製药市场

预计 2025 年生物製药市场规模为 4,582.1 亿美元，到 2032 年将达到 7,552.6 亿美元，2025 年至 2032 年的复合年增长率为 7.4%。

生物製药是由生物来源製造、萃取或半合成的治疗药物。生物製药涵盖范围广泛，例如疫苗、治疗性蛋白质、血液及血液成分以及组织。生物製药是现代科学最尖端、最杰出的成就之一。

市场动态：

慢性病、感染疾病和神经系统疾病负担的增加、老年人口的增加、研发的增加以及 COVID-19（大流行）的爆发是预计将促进全球生物製药市场成长的主要因素。

例如，Phanes Therapeutics, Inc. 于2022年10月获得美国食品药物管理局 (FDA) 的批准，启动PT217的I期临床试验。 PT217是一种正在研究的抗Delta样配体3 (DLL3)/抗分化簇47 (CD47)双特异性抗体，用于治疗美国食品药物管理局(SCLC) 和其他神经内分泌癌患者。 PT217最近获得了FDA授予的治疗SCLC的孤儿药资格。

本研究的主要特点

• 本报告对全球生物製药市场进行了详细分析，并以 2024 年为基准年，给出了 2025 年至 2032 年预测期内的市场规模和年复合成长率（CAGR%）。
• 它还强调了各个领域的潜在商机，并说明了该市场的有吸引力的投资提案矩阵。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
• 它根据公司亮点、产品系列、主要亮点、财务表现和策略等参数，介绍了全球生物製药市场的主要企业概况。
• 本报告的见解将使负责人和企业经营团队能够就未来的产品发布、新兴车型、市场扩张和行销策略做出明智的决策。
• 全球生物製药市场报告针对该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员可以透过分析全球生物製药市场所使用的各种策略矩阵来促进决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章市场动态、法规与趋势分析

• 市场动态
  • 患者和老年人口数量不断增加
  • 高端製造要求
  • COVID-19（全球大流行）疫情
• 影响分析
• 主要亮点
• 监管情景
• 产品发布/核准
• PEST分析
• 波特分析
• 併购场景

第四章全球生物製药市场-冠状病毒（COVID-19）大流行的影响

• COVID-19流行病学
• 供需侧分析
• 经济影响

5. 2020-2032 年全球生物製药市场（依产品类型）

• 单株抗体
• 重组生长因子
• 精製蛋白质
• 重组蛋白
• 重组激素
• 疫苗
• 重组酵素
• 细胞和基因治疗
• 合成免疫调节剂
• 其他产品类型

6. 2020 年至 2032 年全球生物製药市场（依治疗应用）

• 肿瘤学
• 发炎和感染疾病疾病
• 自体免疫疾病
• 代谢紊乱
• 荷尔蒙失调
• 心血管疾病
• 神经系统疾病
• 其他疾病

7. 2020-2032 年全球生物製药市场（按地区）

• 北美洲
• 欧洲
• 亚太地区
• 拉丁美洲
• 中东和非洲

第八章 竞争态势

• Amgen Inc.
• Abbvie Inc.
• GlaxoSmithKline PLC
• Pfizer Inc.
• Novo Nordisk AS
• Novartis AG
• Johnson & Johnson
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd.

第九章 章节

• 调查方法
• 关于出版商

Biopharmaceuticals Market is estimated to be valued at USD 458.21 Bn in 2025 and is expected to reach USD 755.26 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.4% from 2025 to 2032.

A biopharmaceutical is a therapeutic drug manufactured in, extracted from, or semi-synthesized from biological sources. Biopharmaceuticals include a wide range of products such as vaccines, therapeutic proteins, blood and blood components, tissues, etc. Biopharmaceuticals are among the most sophisticated and elegant achievements of modern science.

Market Dynamics:

Increasing burden of chronic, infectious, and neurological diseases, growing geriatric population, increase in research and development (R&D), and outbreak of COVID-19 (pandemic) are major factors expected to augment the growth of the global biopharmaceuticals market.

For instance, in October 2022, Phanes Therapeutics, Inc. received clearance from the US Food and Drug Administration (FDA) to commence Phase I studies with PT217, its anti-Delta-like ligand 3 (DLL3)/anti-Cluster of differentiation 47 (CD47) bispecific antibody being developed for patients with small cell lung cancer (SCLC) and other neuroendocrine cancer. PT217 recently been granted an orphan drug designation by the FDA for the treatment of SCLC.

Key features of the study:

• This report provides in-depth analysis of the global biopharmaceuticals market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global biopharmaceuticals market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Amgen Inc., GlaxoSmithKline PLC, Pfizer Inc., Novo Nordisk AS, Novartis AG, Johnson & Johnson, Eli Lilly and Company, Bristol-Myers Squibb Company, Abbvie Inc., and F. Hoffmann-La Roche Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global biopharmaceuticals market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biopharmaceuticals market.

Detailed Segmentation:

• Global Biopharmaceuticals Market, By Product Type:
  • Monoclonal Antibodies
  • Recombinant Growth Factors
  • Purified Proteins
  • Recombinant Proteins
  • Recombinant Hormones
  • Vaccines
  • Recombinant Enzymes
  • Cell and Gene Therapies
  • Synthetic Immunomodulators
  • Other Product Types
• Global Biopharmaceuticals Market, By Therapeutic Application:
  • Oncology
  • Inflammatory and Infectious Diseases
  • Autoimmune Disorders
  • Metabolic Disorders
  • Hormonal Disorders
  • Cardiovascular Diseases
  • Neurological Diseases
  • Other Diseases
• Global Biopharmaceuticals Market, By Geography:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
• Company Profiles:
  • Amgen Inc.
  • Abbvie Inc.
  • GlaxoSmithKline PLC
  • Pfizer Inc.
  • Novo Nordisk AS
  • Novartis AG
  • Johnson & Johnson
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • F.Hoffmann-La Roche Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Product Type
  • Market Snapshot, By Therapeutic Application
  • Market Snapshot, By Geography
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Rise in patient pool and growing geriatric population
  • High-end manufacturing requirements
  • The outbreak of COVID-19 (global pandemic)
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Biopharmaceuticals Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Biopharmaceuticals Market, By Product Type, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Monoclonal Antibodies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Recombinant Growth Factors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Purified Proteins
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Recombinant Proteins
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Recombinant Hormones
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Vaccines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Recombinant Enzymes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Cell and Gene Therapies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Synthetic Immunomodulators
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Other Product Types
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Biopharmaceuticals Market, By Therapeutic Application, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Oncology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Inflammatory and Infectious Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Autoimmune Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Metabolic Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Hormonal Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Cardiovascular Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Neurological Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Other Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Biopharmaceuticals Market, By Geography, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application, 2020-2032,(US$ Bn)
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application, 2020-2032,(US$ Bn)
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application, 2020-2032,(US$ Bn)
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application, 2020-2032,(US$ Bn)
• Middle East and Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application, 2020-2032,(US$ Bn)

8. Competitive Landscape

• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Abbvie Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline PLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novo Nordisk AS
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• F. Hoffmann-La Roche Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

9. Section

• Research Methodology
• About us